A selective TYK2 inhibitor offers a great opportunity to treat autoimmune diseases delivering a potentially differentiated clinical profile compared to currently approved JAK inhibitors (25, 27, 28, 35). The gene discussed is TYK2; the disease is autoimmune disease.